Hudson Bay Capital Management LP Lineage Cell Therapeutics, Inc. Transaction History
Hudson Bay Capital Management LP
- $25.7 Billion
- Q2 2025
A detailed history of Hudson Bay Capital Management LP transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 48,330 shares of LCTX stock, worth $90,860. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,330
Previous 48,330
-0.0%
Holding current value
$90,860
Previous $43,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
136Shares Held
99.1MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$93.2 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$15.9 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.1 Million6.02% of portfolio
-
Comerica Bank4.6MShares$8.65 Million0.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $319M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...